Not recommended for use during pregnancy or breastfeeding.
Lawley, Alternative dosing regimens of GLP1 receptor agonists may reduce costs and maintain weight loss efficacy, Diabetes Obesity and Metabolism , Feb
2020;155 doi: 10.1016/j.phrs.2020.104722
Biochim Biophys Acta (2013) 1830(5):3289303
Kim JB, Moon W, Park SJ, Park MI, Kim KJ, Lee JN, et al
According to FDA guidelines, these medications are approved for people with a: A body mass index (BMI) of 30 or higher BMI of 27 or higher who have at least one weight-related health condition, like type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease These criteria help ensure that those most likely to benefit from treatment are prioritized